Sompo Japan Nipponkoa Asset Management CO. LTD. Sells 4,970 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Sompo Japan Nipponkoa Asset Management CO. LTD. lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,520 shares of the biopharmaceutical company’s stock after selling 4,970 shares during the quarter. Sompo Japan Nipponkoa Asset Management CO. LTD.’s holdings in Gilead Sciences were worth $2,655,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in GILD. Norges Bank bought a new position in shares of Gilead Sciences during the 4th quarter worth about $859,602,000. Capital Research Global Investors boosted its position in shares of Gilead Sciences by 10.9% during the 4th quarter. Capital Research Global Investors now owns 85,132,885 shares of the biopharmaceutical company’s stock worth $5,531,935,000 after purchasing an additional 8,343,863 shares in the last quarter. Valueworks LLC boosted its position in shares of Gilead Sciences by 7,777.5% during the 4th quarter. Valueworks LLC now owns 4,919,000 shares of the biopharmaceutical company’s stock worth $6,146,000 after purchasing an additional 4,856,556 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Gilead Sciences by 59.2% during the 4th quarter. AQR Capital Management LLC now owns 7,208,716 shares of the biopharmaceutical company’s stock worth $464,529,000 after purchasing an additional 2,682,046 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Gilead Sciences by 15.1% during the 4th quarter. Renaissance Technologies LLC now owns 16,962,944 shares of the biopharmaceutical company’s stock worth $1,102,252,000 after purchasing an additional 2,228,686 shares in the last quarter. 77.34% of the stock is currently owned by institutional investors.

Shares of Gilead Sciences stock traded down $0.16 on Friday, reaching $73.34. 6,157,451 shares of the company traded hands, compared to its average volume of 19,139,120. Gilead Sciences, Inc. has a 52 week low of $60.89 and a 52 week high of $85.97. The company has a 50 day moving average of $77.78 and a 200 day moving average of $70.16. The firm has a market capitalization of $92.20 billion, a PE ratio of 18.85, a PEG ratio of 3.14 and a beta of 0.72. The company has a debt-to-equity ratio of 1.00, a current ratio of 3.04 and a quick ratio of 2.92.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.57 by $0.11. The firm had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.44 billion. Gilead Sciences had a net margin of 21.84% and a return on equity of 35.44%. The company’s revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.67 EPS. As a group, analysts anticipate that Gilead Sciences, Inc. will post 6.34 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Friday, June 12th will be issued a $0.68 dividend. This represents a $2.72 annualized dividend and a yield of 3.71%. The ex-dividend date of this dividend is Thursday, June 11th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.30%.

In related news, Director John Francis Cogan sold 2,413 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $67.26, for a total value of $162,298.38. Following the completion of the transaction, the director now directly owns 57,273 shares of the company’s stock, valued at approximately $3,852,181.98. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Brett A. Pletcher sold 10,441 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $70.88, for a total transaction of $740,058.08. Following the completion of the transaction, the executive vice president now directly owns 25,085 shares of the company’s stock, valued at $1,778,024.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 60,585 shares of company stock valued at $4,671,283. 0.13% of the stock is owned by insiders.

GILD has been the topic of a number of research analyst reports. Cowen reissued a “buy” rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Monday, April 13th. ValuEngine lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Friday, May 1st. Cantor Fitzgerald upped their target price on shares of Gilead Sciences from $78.00 to $86.00 and gave the stock an “overweight” rating in a report on Tuesday, April 7th. Cfra upped their target price on shares of Gilead Sciences from $71.00 to $74.00 and gave the stock a “sell” rating in a report on Wednesday, April 29th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $89.00 target price on shares of Gilead Sciences in a report on Monday, April 13th. Seven investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $78.15.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

See Also: Why is a lock-up period needed for an IPO?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.